Changing Phenotypes and Clinical Outcomes Over Time in Microscopic Polyangiitis

[1]  R. Luqmani,et al.  Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. , 2023, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  J. Robson,et al.  ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives , 2022, Journal of inflammation research.

[3]  C. Torp‐Pedersen,et al.  Increasing incidence and improved survival in ANCA-associated vasculitis-a Danish nationwide study. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  A. Vaglio,et al.  Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome , 2020, Clinical kidney journal.

[5]  P. Messa,et al.  ANCA-associated vasculitis with renal involvement , 2018, Journal of Nephrology.

[6]  P. Höglund,et al.  Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis , 2017, RMD Open.

[7]  X. Solanich,et al.  Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides , 2017, Medicine.

[8]  P. Merkel,et al.  Trends in Long‐Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Renal Disease , 2016, Arthritis & rheumatology.

[9]  G. Ruoppolo,et al.  Microscopic polyangiitis: Advances in diagnostic and therapeutic approaches. , 2015, Autoimmunity Reviews.

[10]  F. Moosig,et al.  Current and emerging techniques for ANCA detection in vasculitis , 2014, Nature Reviews Rheumatology.

[11]  S. Ito,et al.  Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study , 2014, Arthritis Research & Therapy.

[12]  C. Kallenberg.  The diagnosis and classification of microscopic polyangiitis. , 2014, Journal of autoimmunity.

[13]  H. Makino,et al.  Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan , 2013, The Journal of Rheumatology.

[14]  R. Sinico,et al.  Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. , 2013, Autoimmunity reviews.

[15]  P. van Paassen,et al.  Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  E. Koh,et al.  Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea , 2012, Rheumatology International.

[17]  H. Makino,et al.  Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan , 2012, Clinical and Experimental Nephrology.

[18]  P. Höglund,et al.  Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. , 2012, Arthritis and rheumatism.

[19]  P. Höglund,et al.  Long-term patient survival in ANCA-associated vasculitis , 2010, Annals of the rheumatic diseases.

[20]  J. Pouchot,et al.  Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. , 2010, Rheumatology.

[21]  P. Villiger,et al.  Microscopic polyangiitis: Clinical presentation. , 2010, Autoimmunity reviews.

[22]  Irmgard Neumann,et al.  Histopathologic classification of ANCA-associated glomerulonephritis. , 2010, Journal of the American Society of Nephrology : JASN.

[23]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[24]  P. van Paassen,et al.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. , 2010, The New England journal of medicine.

[25]  H. Kautiainen,et al.  Survival of patients with Wegener's granulomatosis diagnosed in Finland in 1981–2000 , 2010, Scandinavian journal of rheumatology.

[26]  V. Tesar,et al.  Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.

[27]  L. Jacobsson,et al.  Improved outcome in Wegener’s granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts , 2009, Journal of internal medicine.

[28]  David Steven Scott,et al.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.

[29]  H. Raspe,et al.  Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force , 2007, Annals of the rheumatic diseases.

[30]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[31]  D. Scott,et al.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.

[32]  H. Rupprecht,et al.  ANCA-associated vasculitis with renal involvement: an outcome analysis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  L. Mouthon,et al.  Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. , 2004, Arthritis and rheumatism.

[34]  M. Heller,et al.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.

[35]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[36]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.

[37]  F. Moosig,et al.  Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. , 2016, Rheumatology.

[38]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[39]  M. Heller,et al.  Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. , 2011, Arthritis and rheumatism.

[40]  Aasarod,et al.  Wegener's granulomatosis: clinical course in 108 patients with renal involvement , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  R. Falk,et al.  Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.